Table 1.
Treatment for Opioid Use Disorders – Coverage, Prior Authorization, and Continuing Review, by year
| All Products | ||||
|---|---|---|---|---|
|
| ||||
| N | ||||
| Number of Products | ||||
| 2003 | 7530 | |||
| 2010 | 8427 | |||
| 2014 | 6974 | |||
|
| ||||
| N | % | SE | ||
|
| ||||
| Opioid Treatment Programs | ||||
| Coverage | ||||
| 2003 | 6650 | 64.5 | 2.4 | |
| 2010 | 8301 | 69.0a | 2.0 | |
| 2014 | 5440 | 97.0a | 1.2 | |
| Prior Authorization | ||||
| 2003 | 3990 | 79.1 | 4.6 | |
| 2010 | 7555 | 74.3a | 1.6 | |
| 2014 | 6813 | 36.5a | 2.3 | |
| Continuing Review | ||||
| 2003 | 4056 | 83.7a | 2.9 | |
| 2010 | 6179 | 73.2a,b | 1.6 | |
| 2014 | 6632 | 43.5b | 1.8 | |
|
| ||||
| Buprenorphine Pharmacy* | ||||
| Coverage | ||||
| 2003 | 6965 | 70.0a | 2.4 | |
| 2010 | 8422 | 100.0a | – | |
| Prior Authorization | ||||
| 2003 | 4797 | 7.9a | 1.5 | |
| 2010 | 8402 | 38.9a | 2.6 | |
Significance testing compared 2003 to 2010 and 2010 to 2014. Pairs with the same letter, within a variable, were significantly different at p<.05.
*
Buprenorphine pharmacy was not asked in 2014